Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Active Biotech
Study demonstrates Anyara localizes to tumors that express the target antigen 5T4
November 4th, 2005
In an ongoing clinical phase I study, specific tumor localization of Active Biotech's candidate drug Anyara has now been objectively confirmed. Using positron emission tomography (PET) and radioactively labeled Anyara, drug concentrations in tumor and normal tissues of individual patients have been measured for the first time, demonstrating that Anyara localizes to tumors that express the target antigen 5T4. The study is ongoing at Paterson Institute for Cancer Research and at Christie Hospital, Manchester, U.K. and the first results from this study were to be presented at the U.K. National Cancer Research Institute conference held in Birmingham, U.K. ...
Source: Biotech Law Weekly (2005-11-04)
|
